Uveitis – Pipeline Review, H1 2017
Pharmaceutical and Healthcare disease pipeline guide Uveitis – Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.
Pharmaceutical and Healthcare latest pipeline guide Uveitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Key points to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Global Markets Direct Report Coverage 7
Uveitis – Overview 8
Uveitis – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
FOR ANY QUERY, CONTACT US @ https://www.wiseguyreports.com/enquiry/1271367-uveitis-pipeline-review-h1-2017
Email Us at : email@example.com
Reach Us at : +1 339 368 6938 (US) +44 208 133 9349 (UK)